Placebo-controlled, double-blinded six-month phase 2 trial of ACH-0144471 in patients with low C3 levels due to C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN)

Trial Profile

Placebo-controlled, double-blinded six-month phase 2 trial of ACH-0144471 in patients with low C3 levels due to C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN)

Planning
Phase of Trial: Phase II

Latest Information Update: 02 Nov 2017

At a glance

  • Drugs ACH 4471 (Primary)
  • Indications Membranoproliferative glomerulonephritis
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Nov 2017 According to Achillion media release, company plans to initiate the trial in first half of 2018.
    • 18 Sep 2017 New trial record
    • 11 Sep 2017 According to an Achillion Pharmaceuticals media release, patient dosing is expected in the second half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top